The management of thyroid nodules and cancer in the molecular era

IF 1.2

International Journal of Endocrine Oncology Pub Date : 2015-11-30 DOI:10.2217/IJE.15.18

Ling-sheng Zhou, K. Patel

引用次数: 1

Abstract

The incidence of thyroid cancer is increasing worldwide. Current standards in the diagnosis and management of thyroid cancer are limited by the uncertainty of fine-needle aspiration samples that are indeterminate in nature. Molecular markers have the potential to improve the accuracy of thyroid fine-needle aspiration and to aid the physician in giving a more accurate diagnosis and prognosis. This paper summarizes the various molecular markers currently available.

查看原文本刊更多论文

分子时代甲状腺结节和癌的治疗

甲状腺癌的发病率在世界范围内呈上升趋势。目前甲状腺癌的诊断和治疗标准受到细针穿刺样本不确定性的限制，细针穿刺样本本质上是不确定的。分子标记有可能提高甲状腺细针穿刺的准确性，并帮助医生给出更准确的诊断和预后。本文综述了目前可用的各种分子标记。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

International Journal of Endocrine Oncology ONCOLOGY-

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： International Journal of Endocrine Oncology is a quarterly, peer-reviewed journal that helps the clinician to keep up to date with best practice in this fast-moving field. The journal highlights significant advances in basic and translational research, and places them in context for future therapy. The journal presents the latest research findings in diagnosis and management of endocrine cancer, together with authoritative reviews, cutting-edge editorials and perspectives that highlight hot topics and controversy in the field. Independent drug evaluations assess newly approved medications and their role in clinical practice. The journal welcomes the unsolicited submission of article proposals and original research manuscripts.